CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

Search

CSL Ltd

Geschlossen

BrancheIndustrie

210.17 0.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

209.19

Max

210.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

2B

Verkäufe

-5.7B

2.5B

KGV

Branchendurchschnitt

21.941

38.367

EPS

2.04

Dividendenrendite

1.39

Gewinnspanne

24.437

Angestellte

29,904

EBITDA

-2.4B

858M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+35.44% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.39%

2.26%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-24B

100B

Vorheriger Eröffnungskurs

210.02

Vorheriger Schlusskurs

210.17

Nachrichtenstimmung

By Acuity

38%

62%

142 / 459 Ranking in Industrials

CSL Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Aug. 2025, 03:32 UTC

Wichtige Markttreiber

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18. Aug. 2025, 23:46 UTC

Ergebnisse

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18. Aug. 2025, 22:15 UTC

Ergebnisse

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9. Apr. 2025, 09:39 UTC

Wichtige Markttreiber

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10. Feb. 2025, 21:55 UTC

Ergebnisse

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. Feb. 2025, 21:34 UTC

Ergebnisse

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18. Aug. 2025, 23:46 UTC

Market Talk
Ergebnisse

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18. Aug. 2025, 21:52 UTC

Ergebnisse

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18. Aug. 2025, 21:51 UTC

Ergebnisse

CSL to Cut Up to 15% of Staff>CSL.AU

18. Aug. 2025, 21:49 UTC

Ergebnisse

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18. Aug. 2025, 21:49 UTC

Ergebnisse

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18. Aug. 2025, 21:48 UTC

Ergebnisse

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18. Aug. 2025, 21:47 UTC

Ergebnisse

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18. Aug. 2025, 21:46 UTC

Ergebnisse

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18. Aug. 2025, 21:45 UTC

Ergebnisse

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18. Aug. 2025, 21:45 UTC

Ergebnisse

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18. Aug. 2025, 21:44 UTC

Ergebnisse

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18. Aug. 2025, 21:43 UTC

Ergebnisse

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18. Aug. 2025, 21:43 UTC

Ergebnisse

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18. Aug. 2025, 21:42 UTC

Ergebnisse

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18. Aug. 2025, 21:42 UTC

Ergebnisse

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17. Juni 2025, 02:15 UTC

Market Talk

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9. Apr. 2025, 07:01 UTC

Market Talk

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21. März 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11. Feb. 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10. Feb. 2025, 21:40 UTC

Ergebnisse

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. Feb. 2025, 21:19 UTC

Ergebnisse

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10. Feb. 2025, 21:13 UTC

Ergebnisse

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10. Feb. 2025, 21:12 UTC

Ergebnisse

CSL Interim Dividend US$1.30/Security

10. Feb. 2025, 21:12 UTC

Ergebnisse

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Peer-Vergleich

Kursveränderung

CSL Ltd Prognose

Kursziel

By TipRanks

35.44% Vorteil

12-Monats-Prognose

Durchschnitt 283.415 AUD  35.44%

Hoch 330 AUD

Tief 227.5 AUD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CSL Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

9

Buy

4

Halten

0

Sell

Stimmung

By Acuity

142 / 459 Ranking in Industrie

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat